Mustang Bio Announces Updated Interim Phase I/II Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio, Inc. announced updated interim data from the ongoing Phase I/II clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphomas and chronic lymphocytic leukemia